25 XP   0   0   10

Laboratorio Reig Jofre S.A
Buy, Hold or Sell?

Let's analyse Laboratorio Reig Jofre S.A together

PenkeI guess you are interested in Laboratorio Reig Jofre S.A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Laboratorio Reig Jofre S.A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Laboratorio Reig Jofre S.A

I send you an email if I find something interesting about Laboratorio Reig Jofre S.A.

Quick analysis of Laboratorio Reig Jofre S.A (30 sec.)










What can you expect buying and holding a share of Laboratorio Reig Jofre S.A? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
‚ā¨2.64
Expected worth in 1 year
‚ā¨3.12
How sure are you?
81.8%

+ What do you gain per year?

Total Gains per Share
‚ā¨0.49
Return On Investment
17.1%

For what price can you sell your share?

Current Price per Share
‚ā¨2.86
Expected price per share
‚ā¨2.65 - ‚ā¨3.38
How sure are you?
50%

1. Valuation of Laboratorio Reig Jofre S.A (5 min.)




Live pricePrice per Share (EOD)

‚ā¨2.86

Intrinsic Value Per Share

‚ā¨-0.26 - ‚ā¨1.65

Total Value Per Share

‚ā¨2.37 - ‚ā¨4.29

2. Growth of Laboratorio Reig Jofre S.A (5 min.)




Is Laboratorio Reig Jofre S.A growing?

Current yearPrevious yearGrowGrow %
How rich?$222.3m$212m$10.2m4.6%

How much money is Laboratorio Reig Jofre S.A making?

Current yearPrevious yearGrowGrow %
Making money$10m$8.6m$1.3m13.8%
Net Profit Margin3.0%3.0%--

How much money comes from the company's main activities?

3. Financial Health of Laboratorio Reig Jofre S.A (5 min.)




What can you expect buying and holding a share of Laboratorio Reig Jofre S.A? (5 min.)

Welcome investor! Laboratorio Reig Jofre S.A's management wants to use your money to grow the business. In return you get a share of Laboratorio Reig Jofre S.A.

What can you expect buying and holding a share of Laboratorio Reig Jofre S.A?

First you should know what it really means to hold a share of Laboratorio Reig Jofre S.A. And how you can make/lose money.

Speculation

The Price per Share of Laboratorio Reig Jofre S.A is ‚ā¨2.86. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Laboratorio Reig Jofre S.A.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Laboratorio Reig Jofre S.A, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨2.64. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.12 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Laboratorio Reig Jofre S.A.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps0.134.5%0.134.5%0.113.8%0.093.2%0.103.4%
Usd Book Value Change Per Share0.134.5%0.134.5%0.134.6%0.165.5%0.165.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.000.1%
Usd Total Gains Per Share0.134.6%0.134.6%0.134.6%0.165.6%0.175.8%
Usd Price Per Share2.41-2.41-2.34-3.13-2.55-
Price to Earnings Ratio18.85-18.85-21.29-38.35-57.61-
Price-to-Total Gains Ratio18.45-18.45-17.63-31.92-18.35-
Price to Book Ratio0.85-0.85-0.87-1.22-3.30-
Price-to-Total Gains Ratio18.45-18.45-17.63-31.92-18.35-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.059342
Number of shares326
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.130.16
Usd Total Gains Per Share0.130.16
Gains per Quarter (326 shares)42.5351.93
Gains per Year (326 shares)170.11207.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
111691602206198
213393304411406
325085006617614
436786708822822
548478401110281030
64101610101312341238
75118611801514391446
86135513501716451654
97152415201918501862
107169416902120562070

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%11.00.00.0100.0%17.03.00.085.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.02.00.081.8%13.07.00.065.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%11.00.00.0100.0%12.00.08.060.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.02.00.081.8%14.06.00.070.0%

Fundamentals of Laboratorio Reig Jofre S.A

About Laboratorio Reig Jofre S.A

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers medical devices, cosmetics, parapharmacy, and animal food related products; and biotechnological and health products. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. In addition, the company provides CDMO and CMO services. It sells its products through business partners. The company was founded in 1929 and is based in Barcelona, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.

Fundamental data was last updated by Penke on 2024-06-11 16:12:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Laboratorio Reig Jofre S.A.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Laboratorio Reig Jofre S.A earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 3.0%¬†means that¬†€0.03 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 3.0%. The company is making a profit. +1
  • The TTM is 3.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ3.0%TTM3.0%0.0%
TTM3.0%YOY3.0%0.0%
TTM3.0%5Y2.6%+0.4%
5Y2.6%10Y4.4%-1.8%
1.1.2. Return on Assets

Shows how efficient Laboratorio Reig Jofre S.A is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • 2.8% Return on Assets means that¬†Laboratorio Reig Jofre S.A generated¬†€0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 2.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.8%TTM2.8%0.0%
TTM2.8%YOY2.5%+0.3%
TTM2.8%5Y2.1%+0.8%
5Y2.1%10Y3.6%-1.5%
1.1.3. Return on Equity

Shows how efficient Laboratorio Reig Jofre S.A is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • 4.6% Return on Equity means Laboratorio Reig Jofre S.A generated €0.05¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 4.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.6%TTM4.6%0.0%
TTM4.6%YOY4.2%+0.4%
TTM4.6%5Y3.5%+1.1%
5Y3.5%10Y6.0%-2.5%

1.2. Operating Efficiency of Laboratorio Reig Jofre S.A.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Laboratorio Reig Jofre S.A is operating .

  • Measures how much profit Laboratorio Reig Jofre S.A makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 3.8%¬†means the company generated €0.04 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 3.8%. The company is operating less efficient.
  • The TTM is 3.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ3.8%TTM3.8%0.0%
TTM3.8%YOY3.5%+0.3%
TTM3.8%5Y3.6%+0.2%
5Y3.6%10Y5.4%-1.8%
1.2.2. Operating Ratio

Measures how efficient Laboratorio Reig Jofre S.A is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.96 means that the operating costs are €0.96 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 0.962. The company is less efficient in keeping operating costs low.
  • The TTM is 0.962. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.962TTM0.9620.000
TTM0.962YOY0.965-0.003
TTM0.9625Y0.9620.000
5Y0.96210Y0.979-0.016

1.3. Liquidity of Laboratorio Reig Jofre S.A.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Laboratorio Reig Jofre S.A is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.47¬†means the company has €1.47 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 1.470. The company is just able to pay all its short-term debts.
  • The TTM is 1.470. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.470TTM1.4700.000
TTM1.470YOY1.485-0.016
TTM1.4705Y1.422+0.048
5Y1.42210Y1.758-0.336
1.3.2. Quick Ratio

Measures if Laboratorio Reig Jofre S.A is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.76¬†means the company can pay off €0.76 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 0.756. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.756. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.756TTM0.7560.000
TTM0.756YOY0.816-0.059
TTM0.7565Y0.784-0.028
5Y0.78410Y1.009-0.224

1.4. Solvency of Laboratorio Reig Jofre S.A.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Laboratorio Reig Jofre S.A assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Laboratorio Reig Jofre S.A to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.37¬†means that Laboratorio Reig Jofre S.A assets are¬†financed with 37.5% credit (debt) and the remaining percentage (100% - 37.5%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 0.375. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.375. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.375TTM0.3750.000
TTM0.375YOY0.383-0.008
TTM0.3755Y0.406-0.031
5Y0.40610Y0.378+0.027
1.4.2. Debt to Equity Ratio

Measures if Laboratorio Reig Jofre S.A is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 61.0% means that company has €0.61 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Laboratorio Reig Jofre S.A:

  • The MRQ is 0.610. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.610. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.610TTM0.6100.000
TTM0.610YOY0.632-0.022
TTM0.6105Y0.689-0.079
5Y0.68910Y0.623+0.065

2. Market Valuation of Laboratorio Reig Jofre S.A

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Laboratorio Reig Jofre S.A generates.

  • Above 15 is considered overpriced but¬†always compare¬†Laboratorio Reig Jofre S.A to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 18.85 means the investor is paying €18.85¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Laboratorio Reig Jofre S.A:

  • The EOD is 23.959. Based on the earnings, the company is fair priced.
  • The MRQ is 18.849. Based on the earnings, the company is fair priced.
  • The TTM is 18.849. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD23.959MRQ18.849+5.110
MRQ18.849TTM18.8490.000
TTM18.849YOY21.287-2.438
TTM18.8495Y38.352-19.503
5Y38.35210Y57.614-19.262
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Laboratorio Reig Jofre S.A:

  • The EOD is 35.521. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 27.945. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 27.945. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD35.521MRQ27.945+7.576
MRQ27.945TTM27.9450.000
TTM27.945YOY36.347-8.402
TTM27.9455Y11.616+16.329
5Y11.61610Y128.120-116.504
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Laboratorio Reig Jofre S.A is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.85 means the investor is paying €0.85¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Laboratorio Reig Jofre S.A:

  • The EOD is 1.084. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.853. Based on the equity, the company is cheap. +2
  • The TTM is 0.853. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.084MRQ0.853+0.231
MRQ0.853TTM0.8530.000
TTM0.853YOY0.870-0.017
TTM0.8535Y1.215-0.362
5Y1.21510Y3.303-2.088
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Laboratorio Reig Jofre S.A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1210.1210%0.124-2%0.147-18%0.153-20%
Book Value Per Share--2.6372.6370%2.516+5%2.429+9%1.794+47%
Current Ratio--1.4701.4700%1.485-1%1.422+3%1.758-16%
Debt To Asset Ratio--0.3750.3750%0.383-2%0.406-8%0.378-1%
Debt To Equity Ratio--0.6100.6100%0.632-3%0.689-11%0.623-2%
Dividend Per Share--0.0010.0010%0.001-23%0.002-66%0.002-79%
Eps--0.1190.1190%0.103+16%0.084+42%0.091+32%
Free Cash Flow Per Share--0.0810.0810%0.060+34%-0.018+122%-0.032+139%
Free Cash Flow To Equity Per Share---0.010-0.0100%0.034-130%0.121-109%0.045-123%
Gross Profit Margin---0.378-0.3780%-0.356-6%-0.606+60%-0.044-88%
Intrinsic Value_10Y_max--1.651--------
Intrinsic Value_10Y_min---0.265--------
Intrinsic Value_1Y_max--0.055--------
Intrinsic Value_1Y_min---0.031--------
Intrinsic Value_3Y_max--0.250--------
Intrinsic Value_3Y_min---0.089--------
Intrinsic Value_5Y_max--0.546--------
Intrinsic Value_5Y_min---0.143--------
Market Cap225371157.440+21%177309103.500177309103.5000%172574417.760+3%230258149.788-23%454361847.402-61%
Net Profit Margin--0.0300.0300%0.0300%0.026+14%0.044-33%
Operating Margin--0.0380.0380%0.035+10%0.036+4%0.054-30%
Operating Ratio--0.9620.9620%0.9650%0.9620%0.979-2%
Pb Ratio1.084+21%0.8530.8530%0.870-2%1.215-30%3.303-74%
Pe Ratio23.959+21%18.84918.8490%21.287-11%38.352-51%57.614-67%
Price Per Share2.860+21%2.2502.2500%2.190+3%2.922-23%2.382-6%
Price To Free Cash Flow Ratio35.521+21%27.94527.9450%36.347-23%11.616+141%128.120-78%
Price To Total Gains Ratio23.451+21%18.44918.4490%17.633+5%31.920-42%18.349+1%
Quick Ratio--0.7560.7560%0.816-7%0.784-4%1.009-25%
Return On Assets--0.0280.0280%0.025+12%0.021+38%0.036-21%
Return On Equity--0.0460.0460%0.042+11%0.035+33%0.060-23%
Total Gains Per Share--0.1220.1220%0.124-2%0.149-18%0.155-21%
Usd Book Value--222310402.500222310402.5000%212065885.600+5%204784009.820+9%162481969.862+37%
Usd Book Value Change Per Share--0.1300.1300%0.132-2%0.158-18%0.163-20%
Usd Book Value Per Share--2.8212.8210%2.691+5%2.599+9%1.919+47%
Usd Dividend Per Share--0.0010.0010%0.001-23%0.002-66%0.003-79%
Usd Eps--0.1280.1280%0.110+16%0.090+42%0.097+32%
Usd Free Cash Flow--6787246.5006787246.5000%5078934.530+34%-1515551.174+122%-2442748.832+136%
Usd Free Cash Flow Per Share--0.0860.0860%0.064+34%-0.019+122%-0.034+139%
Usd Free Cash Flow To Equity Per Share---0.011-0.0110%0.037-130%0.129-109%0.048-123%
Usd Market Cap241079527.114+21%189667548.014189667548.0140%184602854.678+3%246307142.828-23%486030868.166-61%
Usd Price Per Share3.059+21%2.4072.4070%2.343+3%3.126-23%2.548-6%
Usd Profit--10062667.90010062667.9000%8672057.900+16%7107086.800+42%7734946.534+30%
Usd Revenue--338119333.600338119333.6000%290049155.000+17%268228344.700+26%201807228.822+68%
Usd Total Gains Per Share--0.1300.1300%0.133-2%0.159-18%0.166-21%
 EOD+4 -4MRQTTM+0 -0YOY+23 -135Y+22 -1410Y+18 -18

3.2. Fundamental Score

Let's check the fundamental score of Laboratorio Reig Jofre S.A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.959
Price to Book Ratio (EOD)Between0-11.084
Net Profit Margin (MRQ)Greater than00.030
Operating Margin (MRQ)Greater than00.038
Quick Ratio (MRQ)Greater than10.756
Current Ratio (MRQ)Greater than11.470
Debt to Asset Ratio (MRQ)Less than10.375
Debt to Equity Ratio (MRQ)Less than10.610
Return on Equity (MRQ)Greater than0.150.046
Return on Assets (MRQ)Greater than0.050.028
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Laboratorio Reig Jofre S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.559
Ma 20Greater thanMa 502.988
Ma 50Greater thanMa 1002.761
Ma 100Greater thanMa 2002.592
OpenGreater thanClose2.950
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets332,444
Total Liabilities124,619
Total Stockholder Equity204,351
 As reported
Total Liabilities 124,619
Total Stockholder Equity+ 204,351
Total Assets = 332,444

Assets

Total Assets332,444
Total Current Assets132,552
Long-term Assets199,892
Total Current Assets
Cash And Cash Equivalents 5,526
Short-term Investments 830
Net Receivables 61,866
Inventory 61,858
Other Current Assets 3,302
Total Current Assets  (as reported)132,552
Total Current Assets  (calculated)133,382
+/- 830
Long-term Assets
Property Plant Equipment 91,625
Goodwill 27,985
Intangible Assets 63,070
Other Assets 0
Long-term Assets  (as reported)199,892
Long-term Assets  (calculated)182,680
+/- 17,212

Liabilities & Shareholders' Equity

Total Current Liabilities90,186
Long-term Liabilities34,433
Total Stockholder Equity204,351
Total Current Liabilities
Short-term Debt 31,305
Short Long Term Debt 25,211
Accounts payable 34,176
Other Current Liabilities 19,419
Total Current Liabilities  (as reported)90,186
Total Current Liabilities  (calculated)110,111
+/- 19,925
Long-term Liabilities
Long term Debt 13,531
Capital Lease Obligations 14,747
Long-term Liabilities  (as reported)34,433
Long-term Liabilities  (calculated)28,278
+/- 6,155
Total Stockholder Equity
Common Stock39,818
Retained Earnings 9,407
Accumulated Other Comprehensive Income 148,365
Other Stockholders Equity 6,761
Total Stockholder Equity (as reported)204,351
Total Stockholder Equity (calculated)204,351
+/-0
Other
Capital Stock39,818
Cash and Short Term Investments 5,526
Common Stock Shares Outstanding 78,804
Current Deferred Revenue5,286
Liabilities and Stockholders Equity 332,444
Net Debt 55,484
Net Invested Capital 243,093
Net Working Capital 42,366
Property Plant and Equipment Gross 176,802
Short Long Term Debt Total 61,010



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312014-09-302013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
52,636
156,395
288,975
317,553
307,497
200,180
183,088
165,377
98,059
83,766
87,407
180,744
187,054
205,633
203,337
219,675
313,615
317,151
324,976
321,191
332,444
332,444321,191324,976317,151313,615219,675203,337205,633187,054180,74487,40783,76698,059165,377183,088200,180307,497317,553288,975156,39552,636
   > Total Current Assets 
25,961
52,391
84,660
109,063
114,688
26,495
26,166
101,927
34,915
13,384
54,014
72,348
75,010
95,048
81,238
81,860
96,422
100,727
108,800
112,301
132,552
132,552112,301108,800100,72796,42281,86081,23895,04875,01072,34854,01413,38434,915101,92726,16626,495114,688109,06384,66052,39125,961
       Cash And Cash Equivalents 
3,223
4,387
13,588
29,892
34,636
1,095
1,392
714
1,943
4,560
8,815
8,350
9,440
8,182
11,689
8,269
10,171
11,591
5,065
6,454
5,526
5,5266,4545,06511,59110,1718,26911,6898,1829,4408,3508,8154,5601,9437141,3921,09534,63629,89213,5884,3873,223
       Short-term Investments 
0
420
3,414
0
0
246
828
82,781
15,544
816
597
4,339
36
39
766
202
213
102
97
298
830
8302989710221320276639364,33959781615,54482,781828246003,4144200
       Net Receivables 
6,860
0
0
34,085
40,681
0
10,292
0
14,169
4,634
20,341
35,329
40,222
53,574
35,161
33,856
45,650
48,198
51,580
54,917
61,866
61,86654,91751,58048,19845,65033,85635,16153,57440,22235,32920,3414,63414,169010,292040,68134,085006,860
       Inventory 
9,755
32,300
34,462
40,310
36,006
4,647
5,162
2,343
2,786
2,574
21,284
23,840
24,893
33,009
27,509
34,431
38,320
40,373
47,638
48,190
61,858
61,85848,19047,63840,37338,32034,43127,50933,00924,89323,84021,2842,5742,7862,3435,1624,64736,00640,31034,46232,3009,755
       Other Current Assets 
6,123
15,284
33,196
4,776
3,365
20,507
8,492
16,089
473
800
2,976
492
418
245
617
115
2,068
463
4,420
2,740
3,302
3,3022,7404,4204632,0681156172454184922,97680047316,0898,49220,5073,3654,77633,19615,2846,123
   > Long-term Assets 
26,675
104,004
204,315
208,490
192,809
173,685
156,922
63,450
63,144
70,382
0
108,395
112,044
110,585
122,099
137,815
217,193
216,424
216,140
208,890
199,892
199,892208,890216,140216,424217,193137,815122,099110,585112,044108,395070,38263,14463,450156,922173,685192,809208,490204,315104,00426,675
       Property Plant Equipment 
37,521
44,271
44,610
47,297
38,624
6,178
631
318
281
183
23,113
24,046
28,646
37,000
46,749
54,728
83,917
85,280
92,387
93,192
91,625
91,62593,19292,38785,28083,91754,72846,74937,00028,64624,04623,1131832813186316,17838,62447,29744,61044,27137,521
       Goodwill 
2,867
50,115
130,544
0
0
102,983
0
0
59,027
59,027
6,843
25,406
25,166
27,947
27,745
27,598
29,730
29,972
29,843
28,972
27,985
27,98528,97229,84329,97229,73027,59827,74527,94725,16625,4066,84359,02759,02700102,98300130,54450,1152,867
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
1,329
1,261
1,190
1,173
605
1,554
2,508
0
0
0
0
00002,5081,5546051,1731,1901,2611,3290000000000
       Intangible Assets 
3,972
2,466
3,211
133,765
130,124
0
71,306
59,720
488
491
2,109
32,453
32,607
32,084
32,521
39,121
85,879
82,832
77,727
70,893
63,070
63,07070,89377,72782,83285,87939,12132,52132,08432,60732,4532,10949148859,72071,3060130,124133,7653,2112,4663,972
       Long-term Assets Other 
-17,685
420
3,415
5,924
663
246
828
82,781
149
8,646
0
13,040
8,938
624
1,358
465
691
854
368
70,893
0
070,8933688546914651,3586248,93813,04008,64614982,7818282466635,9243,415420-17,685
> Total Liabilities 
15,495
77,150
141,240
176,640
175,549
106,593
109,734
78,787
11,306
8,149
42,704
62,572
60,879
72,340
61,778
69,935
135,477
132,673
136,462
122,943
124,619
124,619122,943136,462132,673135,47769,93561,77872,34060,87962,57242,7048,14911,30678,787109,734106,593175,549176,640141,24077,15015,495
   > Total Current Liabilities 
11,273
28,779
51,097
84,619
96,908
94,778
101,452
59,907
10,795
7,176
26,797
41,315
40,553
44,055
34,467
39,047
68,571
77,811
74,914
75,600
90,186
90,18675,60074,91477,81168,57139,04734,46744,05540,55341,31526,7977,17610,79559,907101,45294,77896,90884,61951,09728,77911,273
       Short-term Debt 
5,072
12,342
18,225
39,684
46,411
63,754
83,766
47,881
1,526
1,633
14,312
10,778
7,307
13,285
6,080
5,186
14,100
14,231
18,327
23,831
31,305
31,30523,83118,32714,23114,1005,1866,08013,2857,30710,77814,3121,6331,52647,88183,76663,75446,41139,68418,22512,3425,072
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
14,312
10,182
6,721
12,692
4,729
3,649
6,518
9,210
12,727
18,516
25,211
25,21118,51612,7279,2106,5183,6494,72912,6926,72110,18214,3120000000000
       Accounts payable 
2,602
13,759
25,228
32,195
26,110
14,192
1,195
10,444
6,544
3,801
10,679
21,137
23,268
22,127
23,975
29,911
31,144
32,981
35,067
29,061
34,176
34,17629,06135,06732,98131,14429,91123,97522,12723,26821,13710,6793,8016,54410,4441,19514,19226,11032,19525,22813,7592,602
       Other Current Liabilities 
3,601
1,871
5,429
12,427
22,471
15,084
16,491
585
2,725
1,443
12,120
35
246
130
2,615
1,948
15,000
15,000
2,055
18,900
19,419
19,41918,9002,05515,00015,0001,9482,6151302463512,1201,4432,72558516,49115,08422,47112,4275,4291,8713,601
   > Long-term Liabilities 
4,223
48,371
90,143
92,021
78,641
11,815
8,282
18,880
511
973
0
21,257
20,326
28,285
27,311
30,889
66,906
54,862
61,548
47,343
34,433
34,43347,34361,54854,86266,90630,88927,31128,28520,32621,257097351118,8808,28211,81578,64192,02190,14348,3714,223
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
42,794
49,056
37,409
0
037,40949,05642,79400000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
5,592
8,624
9,703
10,750
10,220
9,833
24,410
12,068
12,492
13,629
0
013,62912,49212,06824,4109,83310,22010,7509,7038,6245,5920000000000
> Total Stockholder Equity
37,141
79,245
147,735
140,913
131,948
93,587
73,354
86,590
86,753
75,617
44,678
118,144
126,173
133,309
141,605
149,799
178,200
184,546
188,594
194,634
204,351
204,351194,634188,594184,546178,200149,799141,605133,309126,173118,14444,67875,61786,75386,59073,35493,587131,948140,913147,73579,24537,141
   Common Stock
18,490
24,654
32,871
32,871
32,871
32,871
32,871
32,871
32,871
32,871
2,964
126,428
126,428
31,607
32,077
32,525
38,031
38,401
38,716
39,211
39,818
39,81839,21138,71638,40138,03132,52532,07731,607126,428126,4282,96432,87132,87132,87132,87132,87132,87132,87132,87124,65418,490
   Retained Earnings 
3,057
3,721
9,892
3,841
1,491
-44,907
-65,108
-48,568
-49,612
-60,748
40,445
2,308
8,750
7,676
8,828
9,266
4,942
5,672
5,092
8,107
9,407
9,4078,1075,0925,6724,9429,2668,8287,6768,7502,30840,445-60,748-49,612-48,568-65,108-44,9071,4913,8419,8923,7213,057
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,000
19,000
19,000
0
019,00019,00019,00000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
15,593
50,870
104,972
104,201
97,586
105,623
105,591
102,287
103,494
103,494
1,269
-10,593
-9,005
94,026
100,700
108,008
12,920
11,620
11,504
8,078
6,761
6,7618,07811,50411,62012,920108,008100,70094,026-9,005-10,5931,269103,494103,494102,287105,591105,62397,586104,201104,97250,87015,593



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.